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As the effect of renin-angiotensin system (RAS) blockade on b-cells in clinical
situations remains unclear, new evidence has been presented that angiotensin-
converting enzyme (ACE) inhibitors and angiotensin || receptor blockers (ARBs)
may delay or prevent the development of insulin resistance and diabetes through
novel mechanisms. This study aimed to determine the effects of ARBs on insulin
excretion by b-cells. Hypertensive patients with impaired glucose tolerance were
randomly divided into two groups: group A (n=6), which received 8 mg/day of
oral candesartan for three months, and controls (n=6). Before and after adminis-
tration, a 75 g oral glucose tolerance test was conducted to compare various
parameters. No significant differences in age, body mass index (BMI), systolic
blood pressure (SBP), diastolic blood pressure (DBP), fasting glucose, or fasting
immunoreactive insulin (IRI) were identified between the groups before adminis-
tration. After three months, there were no significant changes in BMI, SBP, and
DBP for the controls and in BMI and DBP for group A. However, SBP was signifi-
cantly decreased from 144 ± 2.6 mmHg to 125 ± 4.6 mmHg in group A. Insulino-
genic index tended to be slightly decreased for controls, but was significantly
increased from 0.32 ± 0.0 to 0.47 ± 0.1 for group A. No significant changes in
HOMA-R were identified in either group. To the best of our knowledge, no previ-
ous studies have documented a RAS inhibitor improving early-phase insulin
response; thus, the present study may be the first of its kind.
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Introduction
Recent trials have suggested that inhibitors of the renin-angiotensin system (RAS), such as
angiotensin-converting enzyme (ACE) inhibitors and angiotensin || receptor blockers
(ARBs), may reduce the incidence of new-onset of diabetes in patients with or without
hypertension and at a higher risk of developing diabetes (1). This reduction has been
explained by hemodymic effects, such as improved delivery of insulin and glucose to
peripheral skeletal muscle, and nonhemodynamic effects, such as direct effects on glucose
transport and insulin signaling pathways, all of which decrease insulin resistance (2,3).
There is some evidence now to suggest that the pancreas may contain an in situ active
RAS, which appears to be upregulated in animal models of type 2 diabetes (4,5). ACE
inhibitors and ARBs may thus act by attenuating the deleterious effects of angiotensin ||
on vasoconstricton, fibrosis, inflammation, apoptosis and β-cell death in the pancreas,
thereby protecting critical β-cell mass essential for insulin production. Therefore, these
findings provide a novel mechanism focusing on the β-cell that could partly explain the
reduced incidence of new-onset diabetes observed in clinical trials involving therapy with
ACE inhibitors or ARBs. This study aimed to determine the effects of candesartan on
insulin excretion by β-cells after oral glucose loading in hypertensive patients with
impaired glucose tolerance (IGT).
Research Design and Methods
Hypertensive patients with IGT were enrolled in this study at Saiseikai Niigata Second
Hospital. None of the enrolled patients with IGT had received pharmacologic treatment
before the study. Hypertension was defined by systolic blood pressure (SBP) ≥140 mmHg
and/or diastolic blood pressure (DBP) ≥ 90 mmHg. A standard oral glucose tolerance test
(OGTT) with 75 g of glucose was performed before and after administration. Interpreta-
tions of OGTT data were based on the World Health Organization definition (6), and the
diagnostic criteria for IGT were included in the American Diabetes Association criteria (7).
Insulin resistance expressed as the homeostasis model assessment for insulin resistance
(HOMA-R) was calculated under fasting conditions as follows:
Insulinogenic index is equal to the increase in insulin secretion (immunoreactive insulin
IRI at 30 min - IRI at 0 min) divided by the increase in plasma glucose (plasma glucose at
30 min - plasma glucose at 0 min) (9). Patients were randomly divided into two groups:
controls (n = 6), who were only given dietary guidance, and group A (n = 6), who were
receiving 8 mg/day of oral candesartan for three months in addition to dietary guidance.
All participants (controls+group A) were in a normal dietary education program and
encouraged to exercise regularly during the study. Numerical data are expressed as
mean ± standard error of the mean. Wilcoxon signed rank sum tests were used for statisti-
cal analyses. Informed consent to participate in the study was obtained from each patient.
All study protocols were approved by independent local institutional review boards.
Results
Table 1 shows the clinical characteristics in controls and group A. No significant differences in
age, body mass index (BMI), SBP, DBP, fasting glucose, fasting IRI, or lipid profile were
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identified between the groups before administration. After three months, there was no sig-
nificant change in BMI, SBP, and DBP in the controls, or in BMI and DBP in group
A (see Table 2). However, SBP was significantly decreased from 144 ± 2.6 mmHg to
125 ± 4.6 mmHg in Group A. Figure 1 shows changes in IRI and plasma glucose as mea-
sured by a OGTT before and after glucose administration. In the controls, both plasma
Table 1
Basal characteristics in the controls and group A
Controls Group A
N6 6
Age (y) 53.1 ± 5.1 57.6 ± 4.9
BMI (Kg/m2) 25.0 ± 1.4 25.5 ± 2.0
SBP (mmHg) 140.3 ± 2.7 144.3 ± 2.6
DBP (mmHg) 80.6 ± 3.5 85.3 ± 1.9
Fasting glucose (mg/dl) 112 ± 4.4 105 ± 2.6
Fasting IRI (μU/ml) 7.9 ± 1.7 7.6 ± 0.9
Total cholesterol (mg/dl) 169.5 ± 6.1 168.8 ± 6.4
Triglycerides (mg/dl) 121.5 ± 21 107.3 ± 17
HDL cholesterol (mg/dl) 45.0 ± 3.6 48.1 ± 3.1
LDL cholesterol (mg/dl) 101.0 ± 6.4 99.3 ± 6.3
Values are expressed as number or mean ± standard error of the
mean (SEM). No significant differences in any parameters were identi-
fied between the groups at baseline.
Abbreviations: BMI = body mass index, SBP = systolic blood pres-
sure, DBP = diastolic blood pressure, IRI = immunoreactive insulin.
Table 2
Changes in clinical parameters before and after three months for the controls and group A
Controls Group A
Pre 3M Pre 3M
BMI (Kg/m2) 25.0 ± 1.4 24.5 ± 1.3 25.5 ± 2.0 25.8 ± 2.1
SBP (mmHg) 140.3 ± 2.7 137.0 ± 1.5 144.3 ± 2.6 125.6 ± 4.6*
DBP (mmHg) 80.6 ± 3.5 79.7 ± 3.3 85.3 ± 1.9 83.0 ± 1.3
FPG (mg/dl) 112 ± 4.4 113 ± 3.7 105 ± 2.6 103 ± 3.7
FIRI (μU/ml) 7.9 ± 1.7 7.8 ± 1.6 7.6 ± 0.9 8.3 ± 0.4
AUC for PG
(mg/dl·min) 21412.5 ± 731 19767.5 ± 655* 21432.5 ± 784 20080.0 ± 719
AUC for IRI
(μU/ml·min) 6622.2 ± 1469 4501.0 ± 677 5175.5 ± 940 5395.2 ± 676
HOMA-R 2.18 ± 0.5 2.17 ± 0.4 1.97 ± 0.2 2.16 ± 0.1
Insulinogenic 0.48 ± 0.1 0.46 ± 0.1 0.32 ± 0.0 0.47 ± 0.1*
Values are expressed as mean ± SEM.
Abbreviation: AUC = the area under the curve.
*p < 0.05 vs. baseline data for each group.312 K. Suzuki et al.
glucose level and IRI were significantly decreased after 120 min. In group A, IRI was
slightly increased at 30 min, and did not decrease thereafter. Insulinogenic index tended to
be slightly decreased for the controls, but was significantly increased from 0.32 ± 0.0 to
0.47 ± 0.1 for group A (see Table 2). In terms of individual changes, insulinogenic index
decreased in all the control patients except for one, and increased in all patients in group A
except for one (see Figure 2). No significant changes in HOMA-R were identified in either
Figure 1. Time changes in plasma glucose and IRI after glucose loading before and after three
months for the controls and group A. Solid line = baseline values; dotted line = post-administration
values. Differences between two paired variables were analyzed using the Wilcoxon single-rank
test. *p < 0.05.
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Figure 2. Individual changes in insulinogenic index before and after three months for the controls
and group A. Differences between two paired variables were analyzed using the Wilcoxon single-
rank test. *p < 0.05.
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group (see Table 2). During the study period, normal glucose tolerance was regained in
two patients in each group, and no patients in either group developed type 2 diabetes.
Conclusions
The present results show that three months of candesartan therapy improved early-phase
insulin response in IGT patients with hypertension. RAS blockade in animal models of
type 2 diabetes significantly restores β-cell mass, which could be interpreted as repre-
senting a potentially reparative mechanism, possibly by decreasing oxidative stress and
apoptosis, in addition to attenuating profibrotic pathways (4,5,10). These findings
indicate a novel mechanism focusing on β-cells that could partially explain the reduced
incidence of new-onset of diabetes observed in clinical trials involving therapy with
ACE inhibitors or ARBs. Although the details of the mechanisms of action could not be
clarified, candesartan could improve insulin resistance (11–13) and thus relieve gluc-
otoxicity, improving insulin secretion. Another possibility is that candesartan acts
directly on pancreatic β-cells to improve early-phase insulin response. In the present
study, no changes were noted in HOMA-R, an insulin resistance marker, suggesting that
the latter mechanism is mainly responsible. For reason why HOMA-R was not changed
after the administration of candesartan, we speculate that candesartan did not improve
clinical insulin sensitivity because the study period was relatively short (i.e., six
months). To the best of our knowledge, no previous studies have documented a RAS
inhibitor improving early-phase insulin response. Thus, the present study is the first of
its kind. Subjects in the present study displayed IGT where insulin secretion was rela-
tively maintained, and a similar study is needed in patients with type 2 diabetes where
insulin secretion is somewhat depressed.
Major limitations of the present study were that we examined only a small number of
patients and the study period was relatively short (i.e., six months). Therefore, larger stud-
ies are needed to further elucidate the insulin secretory effect of candesartan during long-
term follow-up.
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